Phosphatidylinositol 4-kinase III beta is the target of oxoglaucine and pachypodol (Ro 09-0179) for their anti-poliovirus activities, and is located at upstream of the target step of brefeldin A

Microbiology and Immunology

Volumn 59, Issue 6, 2015, Pages 338-347

  Arita, Minetaro ^a   Philipov, Stefan ^b   Galabov, Angel S ^c  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b INSTITUTE OF ORGANIC CHEMISTRY   (Bulgaria)

^c BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

Author keywords

Oxoglaucine; Pachypodol (Ro 09 0179); Phosphatidylinositol 4 kinase III beta; Poliovirus

Indexed keywords

3 (3,4 DIMETHOXYPHENYL) 2,5 DIMETHYL N [2 (4 MORPHOLINYL)ETHYL]PYRAZOLO (1,5 A) PYRIMIDINE 7 AMINE; ANTIVIRUS AGENT; BREFELDIN A; ENZYME INHIBITOR; GUANIDINE; OXOGLAUCINE; OXYSTEROL BINDING PROTEIN INHIBITOR; PACHYPODOL; PHOSPHATIDYLINOSITOL 4 KINASE III BETA; PHOSPHATIDYLINOSITOL 4 KINASE III BETA INHIBITOR; PHOSPHATIDYLINOSITOL KINASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; APOMORPHINE; PHOSPHATIDYLINOSITOL 4-KINASE IIIBETA, HUMAN; PHOSPHOTRANSFERASE; QUERCETIN;

ANTIPOLIO VIRUS ACTIVITY; ARTICLE; CELLULAR PARAMETERS; CYTOTOXICITY TEST; DRUG ACTIVITY; DRUG TARGETING; EMBRYO; GOLGI COMPLEX; GOLGI DISASSEMBLY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; POLIOMYELITIS VIRUS; RNA SYNTHESIS; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

PICORNAVIRIDAE; POLIOVIRUS;

ANTIVIRAL AGENTS; APOMORPHINE; BREFELDIN A; HUMANS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLIOVIRUS; QUERCETIN; VIRUS REPLICATION;

EID: 84931838518     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12261     Document Type: Article

References (58)

1. Kuzmanov B.A., Philipov S.A., Deligiozova-Gegova I.B. (1992) Comparative photochemical and chemosystematic research of populations of Glaucinum flavum Cranz in Bulgaria. Fitologia 43: 52-7.
2. Philipov S., Ivanovska N., Nikolova P. (1998) Glaucine analogues as inhibitors of mouse splenocyte activity. Die Pharmazie 53: 694-8.
3. Galabov A.S., Nikolaeva L., Philipov S. (1995) Aporphinoid alkaloid glaucinone: a selective inhibitor of poliovirus replication. Antiviral Res 26: A347.
4. Nikolaeva-Glomb L., Philipov S., Galabov A.S. (2007) Oxoglaucin - enterovirus replication inhibitor: study on the antiviral spectrum, mode of action and development of resistance (in Bulgarian). J Bulg Acad Sci 120: 22-6.
5. Nikolaeva-Glomb L., Philipov S., Galabov A.S. (2008) A new highly potent antienteroviral compound. In Georgiev V.S., Western K.A., McGowan J.J., eds. National Institute of Allergy and Infectious Diseases, NIH, Vol 1 Frontiers in Research. Totowa, NJ: Humana Press, pp. 199-202.
6. Georgieva I., Galabov A.S. (2008) Oxoglaucine: a new highly promising antiviral compound with antirhinoviral effect. In Galabov A.S., Doumanova L., eds. Proceedings and Abstracts of Second Congress of Virology (Days of Virology in Bulgaria) with International Participation, Sofia, May 28-31, 2008 The Stephan Angeloff Institute of Microbiology, BAS: 75-81.
7. Salvati A.L., De Dominicis A., Tait S., Canitano A., Lahm A., Fiore L. (2004) Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus. Antimicrob Agents Chemother 48: 2233-43.
8. Lin Y.J., Chang Y.C., Hsiao N.W., Hsieh J.L., Wang C.Y., Kung S.H., Tsai F.J., Lan Y.C., Lin C.W. (2012) Fisetin and rutin as 3C protease inhibitors of enterovirus A71. J Virol Methods 182: 93-8.
9. Wang J., Su H., Zhang T., Du J., Cui S., Yang F., Jin Q. (2014) Inhibition of Enterovirus 71 replication by 7-hydroxyflavone and diisopropyl-flavon7-yl Phosphate. PLoS ONE 9: e92565.
10. Wang J., Zhang T., Du J., Cui S., Yang F., Jin Q. (2014) Anti-enterovirus 71 effects of chrysin and its phosphate ester. PLoS ONE 9: e89668.
11. Tsuchiya Y., Shimizu M., Hiyama Y., Itoh K., Hashimoto Y., Nakayama M., Horie T., Morita N. (1985) Antiviral activity of natural occurring flavonoids in vitro. Chem Pharm Bull (Tokyo) 33: 3881-6.
12. Castrillo J.L., Vanden Berghe D., Carrasco L. (1986) 3-Methylquercetin is a potent and selective inhibitor of poliovirus RNA synthesis. Virology 152: 219-27.
13. De Meyer N., Haemers A., Mishra L., Pandey H.K., Pieters L.A., Vanden Berghe D.A., Vlietinck A.J.(1991) 4′-Hydroxy-3-methoxyflavones with potent antipicornavirus activity. J Med Chem 34: 736-46.
14. Zhu Q.C., Wang Y., Liu Y.P., Zhang R.Q., Li X., Su W.H., Long F., Luo X.D., Peng T. (2011) Inhibition of enterovirus 71 replication by chrysosplenetin and penduletin. Eur J Pharm Sci 44: 392-8.
15. Ishitsuka H., Ohsawa C., Ohiwa T., Umeda I., Suhara Y. (1982) Antipicornavirus flavone Ro 09- 0179. Antimicrob Agents Chemother 22: 611-6.
16. Rodriguez P.L., Carrasco L. (1992) Gliotoxin: inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol. J Virol 66: 1971-6.
17. Hsu N.Y., Ilnytska O., Belov G., Santiana M., Chen Y.H., Takvorian P.M., Pau C., Van Der Schaar H., Kaushik-Basu N., Balla T., Cameron C.E., Ehrenfeld E., Van Kuppeveld F.J., Altan-Bonnet N. (2010) Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141: 799-811.
18. Arita M. (2014) Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure. Microbiol Immunol 58: 239-56.
19. Roulin P.S., Lotzerich M., Torta F., Tanner L.B., Van Kuppeveld F.J., Wenk M.R., Greber U.F. (2014) Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER-golgi interface. Cell Host Microbe 16: 677-90.
20. Strating J.R., Van Der Linden L., Albulescu L., Bigay J., Arita M., Delang L., Leyssen P., Van Der Schaar H.M., Lanke K.H., Thibaut H.J., Ulferts R., Drin G., Schlinck N., Wubbolts R.W., Sever N., Head S.A., Liu J.O., Beachy P.A., De Matteis M.A., Shair M.D., Olkkonen V.M., Neyts J., Van Kuppeveld F.J. (2015) Itraconazole inhibits Enterovirus replication by targeting the oxysterol-binding protein. Cell Rep. 10: 600-15.
21. Hellen C.U., Witherell G.W., Schmid M., Shin S.H., Pestova T.V., Gil A., Wimmer, E. (1993) A cytoplasmic 57-kDa protein that is required for translation of picornavirus RNA by internal ribosomal entry is identical to the nuclear pyrimidine tract-binding protein. Proc Natl Acad Sci USA 90: 7642-6.
22. Wessels E., Duijsings D., Niu T.K., Neumann S., Oorschot V.M., De Lange F., Lanke K.H., Klumperman J., Henke A., Jackson C.L., Melchers W.J., Van Kuppeveld F.J. (2006) A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor G BF1. Dev Cell 11: 191-201.
23. Bedard K.M., Daijogo S., Semler B.L. (2007) A nucleo-cytoplasmic SR protein functions in viral IRES-mediated translation initiation. Embo J 26: 459-67.
24. Arita M., Wakita T., Shimizu H. (2012) Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection. J Virol 86: 5541-53.
25. Rozovics J.M., Chase A.J., Cathcart A.L., Chou W., Gershon P.D., Palusa S., Wilusz J., Semler B.L. (2012) Picornavirus modification of a host mRNA decay protein. mBio 3: e00431-12.
26. Sasaki J., Ishikawa K., Arita M., Taniguchi K. (2012) ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites. EMBO J 31: 754-66.
27. Virgen-Slane R., Rozovics J.M., Fitzgerald K.D., Ngo T., Chou W., Van Der Heden Van Noort G.J., Filippov D.V., Gershon P.D., Semler B.L. (2012) An RNA virus hijacks an incognito function of a DNA repair enzyme. Proc Natl Acad Sci USA 109: 14634-9.
28. Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. (2013) Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol 87: 4252-60.
29. Nchoutmboube J.A., Viktorova E.G., Scott A.J., Ford L.A., Pei Z., Watkins P.A., Ernst R.K., Belov G.A. (2013) Increased long chain acyl-coa synthetase activity and fatty acid import is linked to membrane synthesis for development of Picornavirus replication organelles. PLoS Pathog 9: e1003401.
30. Wikel J.H., Paget C.J., Delong D.C., Nelson J.D., Wu C.Y., Paschal J.W., Dinner A., Templeton R.J., Chaney M.O., Jones N.D., Chamberlin J.W. (1980) Synthesis of syn and anti isomers of 6-[[(hydroxyimino) phenyl]methyl]-1-[(1-methylethyl) sulfonyl]-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J Med Chem 23: 368-72.
31. Arita M., Wakita T., Shimizu H. (2008) Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 89: 2518-30.
32. Arita M., Takebe Y., Wakita T., Shimizu H. (2010) A bifunctional anti-enterovirus compound that inhibits replication and early stage of enterovirus 71 infection. J Gen Virol 91: 2734-44.
33. Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. (2011) Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol 85: 2364-72.
34. Delang L., Paeshuyse J., Neyts J. (2012) The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. Biochem Pharmacol 84: 1400-8.
35. Heinz B.A., Vance L.M. (1995) The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol 69: 4189-97.
36. Arita M., Wakita T., Shimizu H. (2009) Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime. J Gen Virol 90: 1869-79.
37. Sandoval I.V., Carrasco L. (1997) Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J Virol 71: 4679-93.
38. Arita M., Nagata N., Sata T., Miyamura T., Shimizu H. (2006) Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon. J Gen Virol 87: 3317-27.
39. Baltera R.F., Jr., Tershak D.R. (1989) Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J Virol 63: 4441-4.
40. Crotty S., Saleh M.C., Gitlin L., Beske O., Andino R. (2004) The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein. J Virol 78: 3378-86.
41. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., Balla T., Weiss W.A., Williams R.L., Shokat K.M. (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125: 733-47.
42. Eggers H.J., Tamm I (1961) Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole. J Exp Med 113: 657-82.
43. Chang F.R., Wei J.L., Teng C.M., Wu Y.C. (1998) Antiplatelet aggregation constituents from Annona purpurea. J Nat Prod 61: 1457-61.
44. Ivanovska N., Hristova M. (2000) Treatment with oxoglaucine can enhance host resistance to Candida albicans infection of mice with adjuvant arthritis. Diagn Microbiol Infect Dis 38: 17-20.
45. Remichkova M., Dimitrova P., Philipov S., Ivanovska N. (2009) Toll-like receptor-mediated anti-inflammatory action of glaucine and oxoglaucine. Fitoterapia 80: 411-4.
46. Graziose R., Rathinasabapathy T., Lategan C., Poulev A., Smith P.J., Grace M., Lila M.A., Raskin I (2011) Antiplasmodial activity of aporphine alkaloids and sesquiterpene lactones from Liriodendron tulipifera L. J Ethnopharmacol 133: 26-30.
47. Lamarche M.J., Borawski J., Bose A., Capacci-Daniel C., Colvin R., Dennehy M., Ding J., Dobler M., Drumm J., Gaither L.A., Gao J., Jiang X., Lin K., Mckeever U., Puyang X., Raman P., Thohan S., Tommasi R., Wagner K., Xiong X., Zabawa T., Zhu S., Wiedmann B. (2012) Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob Agents Chemother 56: 5149-56.
48. Mcnamara C.W., Lee M.C., Lim C.S., Lim S.H., Roland J., Nagle A., Simon O., Yeung B.K., Chatterjee A.K., Mccormack S.L., Manary M.J., Zeeman A.M., Dechering K.J., Kumar T.R., Henrich P.P., Gagaring K., Ibanez M., Kato N., Kuhen K.L., Fischli C., Rottmann M., Plouffe D.M., Bursulaya B., Meister S., Rameh L., Trappe J., Haasen D., Timmerman M., Sauerwein R.W., Suwanarusk R., Russell B., Renia L., Nosten F., Tully D.C., Kocken C.H., Glynne R.J., Bodenreider C., Fidock D.A., Diagana T.T., Winzeler E.A. (2013) Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504: 248-53.
49. Belov G.A., Nair V., Hansen B.T., Hoyt F.H., Fischer E.R., Ehrenfeld E. (2012) Complex dynamic development of poliovirus membranous replication complexes. J Virol 86: 302-12.
50. Richards A.L., Soares-Martins J.A., Riddell G.T., Jackson W.T. (2014) Generation of unique poliovirus RNA replication organelles. mBio 5: e00833-13.
51. Rust R.C., Landmann L., Gosert R., Tang B.L., Hong W., Hauri H.P., Egger D., Bienz K. (2001) Cellular COPII proteins are involved in production of the vesicles that form the poliovirus replication complex. J Virol 75: 9808-18.
52. Belov G.A., Kovtunovych G., Jackson C.L., Ehrenfeld E. (2010) Poliovirus replication requires the N-terminus but not the catalytic Sec7 domain of ArfGEF G BF1. Cell Microbiol 12: 1463-79.
53. Schulte M.B., Draghi J.A., Plotkin J.B., Andino R. (2015) Experimentally guided models reveal replication principles that shape the mutation distribution of RNA viruses. eLife 4: e03753.
54. Irurzun A., Perez L., Carrasco L. (1992) Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. Virology 191: 166-75.
55. Van Der Schaar H.M., Leyssen P., Thibaut H.J., De Palma A., Van Der Linden L., Lanke K.H., Lacroix C., Verbeken E., Conrath K., Macleod A.M., Mitchell D.R., Palmer N.J., Van De Poel H., Andrews M., Neyts J., Van Kuppeveld F.J. (2013) A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIbeta. Antimicrob Agents Chemother 57: 4971-81.
56. Vassileva-Pencheva R., Galabov A.S. (2010) Avoiding drug-resistance development by novel approach of combining anti-enteroviral substances against coxsackievirus B1 infection in mice. Antiviral Res 85: 366-72.
57. Fox M.P., Otto M.J., Mckinlay M.A. (1986) Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother 30: 110-16.
58. Spickler C., Lippens J., Laberge M.K., Desmeules S., Bellavance E., Garneau M., Guo T., Hucke O., Leyssen P., Neyts J., Vaillancourt F.H., Decor A., O'meara J., Franti M., Gauthier A. (2013) Phosphatidylinositol 4-kinase III beta is essential for replication of human Rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob Agents Chemother 57: 3358-68.